Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51672-1338-08 51672-1338 Prednisolone Acetate Flo-Pred 16.7 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 17, 2008 Feb. 12, 2010 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
69097-0372-47 69097-0372 Docetaxel Anhydrous Docetaxel Anhydrous 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 24, 2018 Aug. 26, 2020 In Use
83831-0103-16 83831-0103 Docetaxel DOCIVYX 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
70121-1223-01 70121-1223 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 19, 2018 In Use
43598-0389-57 43598-0389 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous April 22, 2019 In Use
47335-0939-40 47335-0939 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
72485-0216-08 72485-0216 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 15, 2020 In Use
00955-1022-08 00955-1022 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 23, 2016 In Use
65597-0504-04 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0504-28 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
43598-0771-11 43598-0771 LEVOLEUCOVORIN LEVOLEUCOVORIN 175.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Sept. 26, 2018 In Use
16714-0890-01 16714-0890 LEVOLEUCOVORIN LEVOLEUCOVORIN 175.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Sept. 26, 2018 In Use
00781-3201-94 00781-3201 Levoleucovorin Levoleucovorin 175.0 mg/17.5mL Ancillary Therapy Chemoprotective Antidote Intravenous April 23, 2015 April 30, 2023 No Longer Used
68152-0112-01 68152-0112 levoleucovorin KHAPZORY 175.0 mg/3.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Jan. 2, 2019 In Use
72893-0004-01 72893-0004 Levoleucovorin KHAPZORY 175.0 mg/3.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Jan. 2, 2019 In Use
16729-0130-53 16729-0130 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 7, 2017 In Use
16729-0130-54 16729-0130 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 7, 2017 In Use
40051-0608-11 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0608-12 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0608-13 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0608-51 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0608-52 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0608-53 40051-0608 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use

Found 10,000 results in 8 millisecondsExport these results